

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 30, 2025

**MICROBOT MEDICAL INC.**  
(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

000-19871  
(Commission  
File Number)

94-3078125  
(IRS Employer  
Identification No.)

175 Derby St., Bld. 27  
Hingham, MA 02043  
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value	MBOT	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure.**

On April 30, 2025, Microbot Medical Inc. (the “Company”) released updated presentation materials, which will be posted on its website at [www.microbotmedical.com](http://www.microbotmedical.com). The Company is not undertaking to update these presentation materials.

The presentation materials are also furnished as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).

**Item 9.01. Financial Statements and Exhibits.**

*(d) Exhibits*

<b>Exhibit Number</b>	<b>Description</b>
99.1	<a href="#">Presentation Materials</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**MICROBOT MEDICAL INC.**

By: /s/ Harel Gadot  
Name: Harel Gadot  
Title: Chief Executive Officer, President and Chairman

---

Date: April 30, 2025

---



**liberty**<sup>™</sup>  
microbot medical  
ENDOVASCULAR ROBOTIC SYSTEM

*Redefining Endovascular Robotics*

# Safe Harbor Statement

---



This document (together with any oral statements made in connection with this document) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, relating to future events or the future financial performance and operations of Microbot Medical, Inc. and its subsidiaries. Forward-looking statements, which involve assumptions and describe Microbot's intent, belief or current expectations about its business opportunities, prospects, performance and results, are generally identifiable by use of the words "may," "could," "should," "will," "would," "expect," "anticipate," "plan," "potential," "estimate," "believe," "intend," "project," "forecast," the negative of such words and other variations on such words or similar terminology. All statements other than statements of historical fact could be deemed forward-looking statements, including, but not limited to: the Company's need for and ability to obtain additional working capital to continue its transition to a commercially focused company; market conditions; risks inherent in the development and/or commercialization of the LIBERTY® Endovascular Robotic System; uncertainty in the results of regulatory pathways and regulatory approvals, including whether the U.S. Food and Drug Administration will timely grant 510(k) clearance to commercially market LIBERTY® in the United States if at all; uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and the recent announcement of tariffs on imports into the U.S.; disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries; maintenance of intellectual property rights; our ability to leverage the experience of our management team; and any statements or assumptions underlying any of the items mentioned. These forward-looking statements are not guarantees of future performance and by their nature involve known and unknown risks and uncertainties that may cause actual opportunities, prospects, performance and results to vary from those presented in this document, and those variances may be material. In evaluating such statements, prospective investors should carefully consider the various risks and uncertainties identified in Microbot's public filings with the Securities and Exchange Commission (the "SEC"), such as market risk, liquidity risk, competitive risk, regulatory risk and other commonly recognized forms of risk relating to Microbot and its securities. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this document might not occur. Microbot is not obligated to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of Microbot's securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

---



## Large and Emergent Market

- Many endovascular procedures are life and limb saving interventions
- **>6 million** procedures in the USA (15 million worldwide)
- Performed by **>15,000** physicians (USA)
- **>\$40B** annual spend (USA)



## Significant Unmet Needs

- Difficulty navigating complex anatomy
- Healthcare providers at elevated risk of cancer and orthopedic problems
- Shortage of healthcare providers
- Limited access to quality care



## Differentiated Robotic Solution

- LIBERTY®** is the world's 1<sup>st</sup> fully disposable robotic system designed to:
- Improve procedural efficiency
  - Lower procedure costs
  - Reduce risks of radiation exposure and physical strain (ergonomics)
  - Enable access to quality care



## First Mover Advantage

- No commercially available robotic system in the USA for endovascular procedures\*
- First single use robotic system



## Attractive Reimbursement

- High procedure reimbursement for target procedures
- Capacity to incorporate new technologies



## Unique Business Model

- Single use design reduces customer barriers to acquisition
- Improves operational efficiencies
- Eliminates upfront investment in expensive inventory build
- No expensive investment in services infrastructure



## Clear Path to Commercialization

- Completed pre-submission with FDA
- Successfully completed pivotal human clinical trial in the USA
- Filed 510(k) with the FDA in **Dec. 2024**
- Expected commercial launch during **Q2 2025**




## Experienced Team

- Led by a team with a proven track record of leading companies from inception to commercialization
- Supported by board of directors composed of high level, cross functional industry veterans
- Backed by global medical experts in the endovascular space

Source: AcuityMD procedure and physician database  
\* Excluding structural heart procedures

- **>6 million annual endovascular procedures** performed in the US (15 million worldwide)
- **>\$40B spent annually** in the US
- Performed by **15,000 physicians**
  - 9,000 interventional cardiologists
  - 3,000 interventional radiologists<sup>1</sup>
  - 3,000 vascular surgeons
- Performed at **8,000 facilities**
  - 3,500 hospitals
  - 4,500 ambulatory centers (ASCs/OBLs)
- Many endovascular procedures are emergent, life and limb saving interventions



Source: AcuityMD procedure and physician database  
1. Includes interventional neuroradiologists which is a sub-specialty of IR



# Initial Target Market: Peripheral Vascular



Source: AcuityMD database

Endovascular procedures are ripe for disruptive innovation that can improve procedure efficiency, HCP health & safety, while enabling access to quality care for both providers and patients

## Procedure Efficiency

- Managing catheter and guidewire exchanges requires multiple clinical staff to handle the devices, thereby reducing procedure efficiency.
- Less experienced physicians face additional challenges in navigating complex vascular anatomy, negatively impacting procedure times and increasing radiation exposure.

## Radiation Risks

- Endovascular procedures are time consuming and require clinicians to operate near the source of ionizing radiation.
- Despite wearing radiation protection equipment, providers who perform interventional radiology or cardiology procedures are 6 times more likely to develop cataracts and 3 times more likely to develop cancer during their careers.<sup>1</sup>

## Ergonomic Issues

- Endovascular procedures are time consuming, and clinicians stand over the patient while wearing heavy lead protective equipment.
- Due to wearing heavy lead vests/protective equipment while performing the procedures, clinicians are 96% more likely to suffer from lower back pain and 21% more likely to miss work.<sup>2,3</sup>

## Access to Quality Care


- Limited availability of experienced physicians and other staffing shortage
- Lack of capital budget to purchase robotic technology
- Few community hospitals can perform advanced procedures, resulting in patients traveling long distances for life saving healthcare.

1. Andreassi MG, Piccaluga E, Guagliumi G, et al. Occupational health risks in cardiac catheterization laboratory workers. *Circ Cardiovasc Interv.* 2016;9:003273.

2. Andrew S, Abdelmonem M R, Kohli S, et al. (October 18, 2021) Evaluation of Back Pain and Lead Apron Use Among Staff at a District General Hospital. *Cureus* 13(10): e18859. DOI 10.7759/cureus.18859

3. Nicholas M. Orme et al. Occupational Health Hazards of Working in the Interventional Laboratory: A Multisite Case Control Study of Physicians and Allied Staff, *Journal of the American College of Cardiology*, Volume 65, Issue 8,

Robotic manipulation of guidewires and catheters with LIBERTY® was successful in all cases, minimizing radiation exposure and maintaining a desirable safety profile <sup>1</sup>



1. Cornelis F, Gandhi R, Rabkin D, Diaz-Cartelle J. Remote-controlled endovascular navigation with a miniature, single-use, robotic system. LBA15



# Differentiated Robotic Solution

The LIBERTY® Endovascular Robotic System is disruptive technology designed to change the standard of care for endovascular procedures

- Single-use, fully-disposable without need for capital investment
- Empowers physicians to precisely steer guidewires and catheters using a handheld remote control away from the radiation source
- Small footprint that integrates into current procedure workflow
- No additional infrastructure required by the user
- Simple and intuitive set-up in under 5 minutes
- Short-learning curve to proficiency
- Compatible with off the shelf guidewires and catheters







## The LIBERTY® Value Proposition

Improve Access to Robotics and Reduce Complexity	Improved Safety	Lower Costs	Improve Efficiency	Improve Care	Increase Patient Access to Care
<p><b>UNMET NEED:</b> Conventional robotic systems have high acquisition costs which limit access to robotic technology. Most have a large footprint, are difficult to set up, and have a steep learning curve.</p>	<p><b>UNMET NEED:</b> Due to radiation exposure, radiologists and cardiologists are 6X more likely to develop cataracts and 3X more likely to develop cancer during their career.<sup>1</sup> They are 96% more likely to suffer from lower back pain and 21% more likely to miss work from wearing heavy lead vests/protective equipment.<sup>2,3</sup></p>	<p><b>UNMET NEED:</b> Manual procedures require two people to manage the guidewires and catheters.</p>	<p><b>UNMET NEED:</b> Wire exchanges for contrast injections can be tedious and time consuming, which contributes to long procedure times.</p>	<p><b>UNMET NEED:</b> Less experienced physicians are not as skilled steering guidewires and catheters in challenging anatomy.</p>	<p><b>UNMET NEED:</b> Many complex endovascular procedures are not available in community hospitals due to lack of physicians.</p>
<p><b>LIBERTY®</b> eliminates the need for upfront capital purchase, allowing customers greater access to introduce robotics into their practice. It is designed to easily integrate into clinical workflows, with easy set up and a short learning curve to proficiency.</p>	<p><b>LIBERTY®</b> allows physicians to perform procedures away from the radiation source, and without the need to wear heavy lead vests/protective equipment.</p>	<p><b>LIBERTY®</b> holds the wires and catheters, eliminating the need for an extra set of hands.</p>	<p><b>LIBERTY®</b> automates routine tasks like guidewire retraction and return which may reduce procedure times.</p>	<p><b>LIBERTY®</b> is designed to elevate the skill level of less experienced physicians with precise control of guidewires and catheters.</p>	<p><b>LIBERTY®</b> is designed to enable telesurgery which will increase access to experienced physicians. And by removing the need for upfront capital purchase, LIBERTY allows community hospitals greater access to introduce robotics into their practice.</p>

1. Andreassi MG, Piccaluga E, Guagliumi G, et al. Occupational health risks in cardiac catheterization laboratory workers. *Circ Cardiovasc Interv.* 2016;9:003273.

2. Andrew S, Abdelmonem M R, Kohli S, et al. (October 18, 2021) Evaluation of Back Pain and Lead Apron Use Among Staff at a District General Hospital. *Cureus* 13(10): e18859. DOI 10.7759/cureus.18859

3. Nicholas M. Orme et al. Occupational Health Hazards of Working in the Interventional Laboratory: A Multisite Case Control Study of Physicians and Allied Staff, *Journal of the American College of Cardiology*, Volume 65, Issue 8,



# Differentiated Robotic Solution

LIBERTY® is protected by a strong intellectual property portfolio that includes patents and trademarks

**9**  
patents  
issued/allowed  
Worldwide

**21**  
trademarks  
registered  
Worldwide

**59**  
patent  
applications  
pending  
worldwide

US

IL

CN

JP

EU

CA

EPO

HK

**LIBERTY® was designed to eliminate barriers and enable adoption of robotics in endovascular procedures**

Barriers to Adoption	Other Robotic Systems	LIBERTY® Robotic System
<b>Cost of acquisition</b>	<ul style="list-style-type: none"> <li>✓ Large capital investment</li> <li>✓ Disposable procedure kit</li> <li>✓ Annual service agreement</li> </ul>	<ul style="list-style-type: none"> <li>✓ <b>Single-use (disposable) device</b> with no <b>initial acquisition cost</b></li> </ul>
<b>Procedure set-up time</b>	<ul style="list-style-type: none"> <li>✓ <b>20 minutes extra</b> compared to conventional surgery<sup>1</sup></li> </ul>	<ul style="list-style-type: none"> <li>✓ <b>5 minutes</b> to set-up the robot<sup>3</sup></li> </ul>
<b>Learning curve</b>	<ul style="list-style-type: none"> <li>✓ Average <b>40-100 cases</b> depending on the procedure<sup>2</sup></li> </ul>	<ul style="list-style-type: none"> <li>✓ <b>Less than 5 cases</b><sup>3</sup></li> </ul>
<b>Device compatibility</b>	<ul style="list-style-type: none"> <li>✓ Some require use of <b>proprietary instruments and devices</b></li> </ul>	<ul style="list-style-type: none"> <li>✓ Compatible with <b>off the shelf instruments and devices</b></li> </ul>
<b>Complex integration</b>	<ul style="list-style-type: none"> <li>✓ Requires a <b>dedicated room and integration with hospital IT systems</b></li> </ul>	<ul style="list-style-type: none"> <li>✓ Can be used in <b>any angio-suite</b> and <b>does not need to connect with hospital IT</b></li> </ul>

1. Analysis of Procedure Time in Robot-Assisted Surgery: Comparative Study in Laparoscopic Cholecystectomy, Computer Aided Surgery, 8:1, 24-29, DOI: 10.3109/10929080309146099.

2. Systematic review of learning curves in robot-assisted surgery, BJS Open 2020; 4: 27-44.

3. Research report from wet-lab with 9 experienced interventional radiologists. Set-up times and learning curve will vary with user.

## There is currently no commercially robotic system available in the US for endovascular procedures

Several companies are developing robotic solutions due to the attractive market and untapped potential  
Microbot is uniquely positioned for success with our unique design and first mover advantage in the US market

Company	Status	Target Procedures	USA Commercial Availability	No Capital Equipment	No Maintenance Required	No Infrastructure Required	Competitive Outlook
	Completed Clinical Study	Initially Peripheral Vascular, followed by Neurovascular & Cardiology	<b>Q2 2025</b>	✓	✓	✓	Expect FDA clearance in Q2 2025, and CE Mark in 2026.
	On the market (Europe, China)	Cardiology	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	Focused on Europe & China. Large capital system with high cost and complex integration.
<b>LN ROBOTICS</b>	On the market (Korea only)	Cardiology	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	Focused on Korea. Large capital system with high cost and complex integration.
	Development stage	Neurovascular	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	Exited US cardiology market. Changed strategy from PCI to focus on Neurovascular.
 (Latvia)	Development stage	Peripheral Vascular	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	Completed one case in humans. Clinical, regulatory and operational complexity are unknown.
	Development stage	Neuro Vascular	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>	Pre-clinical. Focused on telerobotics with magnetic steering. Cost and operational complexity are unknown.

Targeted procedures have an attractive outpatient reimbursement with capacity to incorporate new technologies including LIBERTY®

Procedure	Description	CPT Code(s)	Avg. Reimbursement
<b>Y90 for Liver Cancer</b>	Part 1 – Mapping procedure Part 2 – Embolization procedure	Dx Angiogram (75726) Coil placement (37242) Embolization (37243) Y90 particles (C2616)	<b>\$43,990.21</b>
<b>Peripheral Embolization</b>	For BPH, Uterine Fibroids, Hemorrhoids, Knee Osteoarthritis	Dx Angiogram (75726) Bland particle embolization (37242)	<b>\$15,734.00</b>
<b>Lower Limb Revascularization</b>	Below the knee Chronic total occlusions	Dx Angiogram (75726) Angioplasty (37242)	<b>\$15,856.00</b>
<b>Vascular Hemorrhage</b>	Place intravascular coils or glue to stop bleeding	Dx Angiogram (75726) Coil placement (37244)	<b>\$15,734.00</b>

2024 Medicare/Medicaid average reimbursement  
Actual reimbursement will vary and may be adjusted for cost of living  
Private insurance typically billed at a higher rate

The fully disposable feature of LIBERTY® offers an attractive business model to position LIBERTY® for commercial success by reducing barriers for entry and increase operational efficiencies for all stakeholders

## No Capital Investment

- No special Capital Expense (CAPEX) approval required by the customer. LIBERTY® can be purchased from the Operational Expense (OPEX) budget which will expedite the purchasing process.
- Cost effective evaluation process for customers at their facility can expedite purchasing decision.
- Eliminates the Company's investment in an expensive upfront and ongoing capital equipment inventory build-up, shipping, storage and management.

## No Maintenance Expense

- Eliminates the cost for Microbot to hire, train, and manage a dedicated field service department.
- Eliminates the cost for Microbot to build dedicated warehouses and maintain inventory of replacement parts.
- Eliminates the cost for customers to pay for service and maintenance expenses.
- Eliminates risk of equipment down time.

## No Custom Infrastructure

- Eliminates the process of fitting the technology to each specific customer (and sometime within a health system), to reduce expenses and expedite purchasing decision.
- Eliminates the investment in establishing, training, supporting and supplying technical team to support installations.
- LIBERTY® does not require investment in dedicated customer staff to provide on-going robotic program support.

## Continuous Consumable Revenue

- Recurring revenue stream based on per device usage (or more) for a single procedure.
- LIBERTY® is a single SKU (Stock Keeping Unit) that can be utilized across many procedures, physicians and departments.



# Clear Path to Commercialization



With the recent and successful completion of many major milestones, LIBERTY® has a clear path to U.S. launch in Q2 2025



**Leadership Team**



**Harel Gadot**  
CEO, President & Chairman  
[LinkedIn](#)



**Simon Sharon**  
Chief Technology Officer  
[LinkedIn](#)



**Juan Diaz-Cartelle, MD**  
Chief Medical Officer  
[LinkedIn](#)



**Rachel Vaknin**  
Chief Financial Officer  
[LinkedIn](#)



**Earl Adamy**  
Vice President of Strategic  
Marketing & Business Dev  
[LinkedIn](#)



**Eran Cohen**  
Vice President  
of Global Integration  
[LinkedIn](#)



**Naama Moav**  
Vice President of HR  
[LinkedIn](#)



**Paul Mullen**  
Vice President of Sales  
[LinkedIn](#)



**Noa Ofer**  
Vice President of QA & RA  
[LinkedIn](#)



**Allison Rosefort**  
Vice President of Marketing  
[LinkedIn](#)

---

**Board of Directors**



**Harel Gadot**  
CEO, President & Chairman  
[LinkedIn](#)



**Martin J. Madden**  
Director  
[LinkedIn](#)



**Tal Wenderow**  
Director  
[LinkedIn](#)



**Scott Burell, CPA**  
Director  
[LinkedIn](#)



**Aileen Stockburger**  
Director  
[LinkedIn](#)



**P. Laxminarain**  
Director  
[LinkedIn](#)



**David Wilson**  
Director  
[LinkedIn](#)

## LIBERTY® is a differentiated solution in a large and emergent market, with clear unmet needs and attractive reimbursement

The endovascular market is large with more than 15 million endovascular procedures performed annually around the world, many of which are life saving and limb saving procedures.

In the U.S., endovascular procedures historically have high reimbursement, with capacity for integrating new technologies like robotics that is expected to add value to all stakeholders.

Microbot is revolutionizing surgical robotics by introducing the world's first single-use, fully-disposable robotic system that improves access to robotic technology by eliminating the expensive capital investment and special infrastructure requirements.

LIBERTY® is designed to allow physicians to remotely perform procedures with precision from the safety of the control room, away from harmful radiation exposure and reduce physical strain (ergonomics)

LIBERTY® is also designed to improve procedural efficiency by eliminating the need for assistance to hold wires and catheters, and to simplify the ability to access complex vascular anatomy.

Microbot achieved meaningful milestones such as receiving an IDE approval from the FDA, successfully completing its pivotal clinical trial and submitting for FDA clearance in December 2024.

USA launch is expected during Q2 2025, followed by other regions that accept FDA cleared devices and a European launch during 2H 2026.



Contact Investor Relations

[ir@microbotmedical.com](mailto:ir@microbotmedical.com)

NASDAQ CM: MBOT

